written on 16.04.2014

Amgen's Bradway nets $13.65M in 2013, sans Onyx bonus


Amgen CEO Robert Bradway nabbed Onyx Pharmaceuticals for $10.4 billion last summer, but that wasn't enough to net him the kind of deal-related bonus some of his peers enjoy. But his take-home increased over last year's haul, which was enough to score him 13th place on the list of biopharma's highest-paid chiefs.